Publications
Publications
Show Results For
-
All HBS Web
(337)
- Faculty Publications (26)
Page 1 of
26
Results
→
Are you looking for?
Skip to content The HBS Digital Initiative brings together perspectives across disciplines to help people understand how technology is transforming...
- 2020
- Working Paper
A General Theory of Identification
By: Iavor Bojinov and Guillaume Basse
What does it mean to say that a quantity is identifiable from the data? Statisticians seem to agree
on a definition in the context of parametric statistical models — roughly, a parameter θ in a model
P = {Pθ : θ ∈ Θ} is identifiable if the mapping θ 7→ Pθ is injective....
View Details
- January 2020
- Case
Celata Bioinnovations
By: John R. Wells and Benjamin Weinstock
In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process....
View Details
Keywords:
Drug Development;
Drug Discovery;
Drug Trials;
Pharmaceutical Companies;
Pharmaceutical Company;
Pharmaceuticals;
Therapeutics;
Biologics;
Biotech;
Biotechnology;
Biopharmacy Company;
Biochemistry;
Technology Commercialization;
Technology Companies;
Drug Testing;
Startup;
Start-up;
Startups;
Start-ups;
Startup Financing;
Strategic Decision Making;
Strategic Decisions;
Strategic Evolution;
Fda;
Food And Drug Administration;
Clinical Trials;
Disease Management;
Market Attractiveness;
Market Entry;
Market Opportunities;
Health Disorders;
Technological Innovation;
Technology;
Commercialization;
Business Startups;
Finance;
Decision Making;
Strategy;
Market Entry and Exit;
Opportunities;
Pharmaceutical Industry;
Biotechnology Industry
- September 2019 (Revised August 2020)
- Case
Engineering an Inclusive Bioeconomy
By: Tarun Khanna, Raffaella Sadun and Susie L. Ma
In 2019, entrepreneur Juan Carlos Castilla-Rubio was developing a project he hoped could generate and share wealth from the natural resources of the Amazon without destroying those resources. His idea, called Earth Bank of Codes (EBC), would create a library of the...
View Details
Keywords:
Decision Making;
Development Economics;
Entrepreneurship;
Innovation and Invention;
Intellectual Property;
Emerging Markets;
Market Design;
Marketplace Matching;
Science;
Genetics;
Natural Environment;
Environmental Sustainability;
Climate Change;
Social Enterprise;
Strategy;
Strategic Planning;
Technology;
Ownership;
Social Psychology;
Trust;
Society;
Biotechnology Industry;
South America;
Amazon Basin
- March 2019
- Article
Crime and Violence: Desensitization in Victims to Watching Criminal Events
By: Rafael Di Tella, Lucia Freira, Ramiro H. Gálvez, Ernesto Schargrodsky, Diego Shalom and Mariano Sigman
We study desensitization to crime in a lab experiment by showing footage of criminal acts to a group of subjects, some of whom have been previously victimized. We measure biological markers of stress and behavioral indices of cognitive control before and after treated...
View Details
- December 2018 (Revised May 2019)
- Case
Darling Ingredients International
By: David E. Bell and Natalie Kindred
Led by CEO Randall Stuewe, Texas-based Darling Ingredients International was a rendering firm with $3.7 billion in 2017 revenues. Since 2003, Darling had transformed from U.S. focused into a global player in the processing of biological waste from meat and foodservice...
View Details
Keywords:
Darling;
Ingredients;
Stuewe;
Rendering;
Animal Byproducts;
Used Cooking Oil;
Uco;
Diamond Green Diesel;
Dgd;
Valero;
Renewable Diesel;
Biofuel;
Recycling;
Carbon;
Lcfs;
Blend;
Blender;
Strategy;
Corporate Strategy;
Renewable Energy;
Food;
Agribusiness;
Expansion;
Diversification;
Growth Management;
Technological Innovation;
Policy;
Government Legislation;
Agriculture and Agribusiness Industry;
Energy Industry;
Food and Beverage Industry;
United States;
Louisiana;
California;
Texas
- 2018
- Chapter
The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century
By: Nicholas Bagley, Benjamin Berger, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
On the 35th anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormous changes in the markets for therapies for rare diseases that have emerged over recent decades. The most prominent example is the fact that the profit-maximizing price of new...
View Details
- Article
The Impact of the 'Open' Workspace on Human Collaboration
By: Ethan Bernstein and Stephen Turban
Organizations’ pursuit of increased workplace collaboration has led managers to transform traditional office spaces into “open,” transparency-enhancing architectures with fewer walls, doors, and other spatial boundaries, yet there is scant direct empirical research on...
View Details
Keywords:
Open Office;
Transparency;
Collaboration;
Collective Intelligence;
Workspace;
Workspace Design;
Architecture;
Cubicles;
Boundaries;
Spatial Boundaries;
Human Behavior;
Propinquity;
Co-location;
Interaction;
Sociometers;
People Analytics;
Buildings and Facilities;
Communication;
Design;
Human Resources;
Leadership;
Management;
Organizational Design;
Organizational Structure;
Networks;
Social and Collaborative Networks;
Technology;
United States
- August 2018
- Article
The Impact of the Entry of Biosimilars: Evidence from Europe
By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby...
View Details
- March 2018 (Revised March 2019)
- Case
Gender and Free Speech at Google (A)
By: Nien-hê Hsieh, Martha J. Crawford and Sarah Mehta
In August 2017, Google fired James Damore, a 28-year-old software engineer who had been employed by the company since 2013. The move came after Damore penned an internal company memo titled “Google’s Ideological Echo Chamber,” which posited that innate biological...
View Details
- 2017
- Working Paper
Crime and Violence: Desensitization in Victims to Watching Criminal Events
By: Rafael Di Tella, Lucía Freira, Ramiro H. Gálvez, Ernesto Schargrodsky, Diego Shalom and Mariano Sigman
We study desensitization to crime in a lab experiment by showing footage of criminal acts to a group of subjects, some of whom have been previously victimized. We measure biological markers of stress and behavioral indices of cognitive control before and after treated...
View Details
- 2017
- Working Paper
Crime and Violence: Desensitization in Victims to Watching Criminal Events
By: Rafael Di Tella, Lucia Freira, Ramiro H. Gálvez, Ernesto Schargrodsky, Diego Shalom and Mariano Sigman
We study desensitization to crime in a lab experiment by showing footage of criminal acts to a group of subjects, some of whom have been previously victimized. We measure biological markers of stress and behavioral indices of cognitive control before and after treated...
View Details
- November 2016
- Case
QuintilesIMS: Biosimilar Marketing in England
By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical...
View Details
- June 2016 (Revised August 2019)
- Case
Numenta: Inventing and (or) Commercializing AI
By: David B. Yoffie, Liz Kind and David Ben Shimol
In March 2016, Donna Dubinsky (co-founder and CEO) and Jeff Hawkins (co-founder) were struggling with a key question: Could Numenta be successful in both creating fundamental technology and building a commercial business? Located in Redwood City, CA, Numenta was...
View Details
- October 2015
- Article
Hormones and Ethics: Understanding the Biological Basis of Unethical Conduct
By: Jooa Julie Lee, Francesca Gino, Ellie Shuo Jin, Leslie K. Rice and Robert A. Josephs
Globally, fraud has been rising sharply over the last decade, with current estimates placing financial losses at greater than $3.7 trillion dollars annually. Unfortunately, fraud prevention has been stymied by lack of a clear and comprehensive understanding of its...
View Details
- July 2011 (Revised January 2013)
- Case
Digital Microscopy Is Making Me Crazy!
By: Willy Shih
For Carl Zeiss Microimaging, modular hardware and software enabled customers to tailor Zeiss's broad range of microscopy systems hardware and software to meet a wide range of needs from basic scientific research in the biological and medical sciences to clinical...
View Details
- April 2011
- Teaching Note
Office of Technology Transfer - Shanghai Institutes for Biological Sciences (TN)
By: Willy Shih and Sen Chai
Teaching Note for 611057.
View Details
- March 2011 (Revised June 2012)
- Case
Office of Technology Transfer - Shanghai Institutes for Biological Sciences
By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland
Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing...
View Details
- January 2011
- Article
Let the Right One In: A Microeconomic Approach to Partner Choice in Mutualisms
By: Marco Archetti, Francisco Ubeda, Drew Fudenberg, Jerry R. Green, Naomi E. Pierce and Douglas W. Yu
One of the main problems impeding the evolution of cooperation is partner choice. When information is asymmetric (the quality of a potential partner is known only to himself), it may seem that partner choice is not possible without signaling. Many mutualisms, however,...
View Details
- May 2007 (Revised September 2008)
- Case
Biocon Limited
By: Krishna G. Palepu and Ananth Chepuri
Biocon Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an innovation-led strategy. This new...
View Details
- January 2007 (Revised January 2007)
- Background Note
Note on the U.S. Food and Drug Administration
By: Robert F. Higgins, Richard G. Hamermesh and Virginia Fuller
Describes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure.
View Details